Based on the information from DrugPatentWatch.com, there are currently patents held for loratadine phenylephrine combinations. Specifically, Sanofi-Aventis holds patents for this combination, which can be found under the brand name Alavert-D 12 Hour [1].

Loratadine is an antihistamine that reduces the effects of natural chemical histamine in the body. Phenylephrine is a decongestant that shrinks blood vessels in the nasal passages. Together, these two active ingredients work to alleviate symptoms of allergies and nasal congestion [2].

Sanofi-Aventis's patent for loratadine phenylephrine combinations extends until 2030 [1]. This means that other companies are unable to produce and sell generic versions of this medication until the patent expires.

It is important to note that while patents can provide pharmaceutical companies with a period of market exclusivity, they can also limit access to affordable medications for consumers. Once the patent expires, however, generic versions of the medication become available, typically at a lower cost [3].

In summary, Sanofi-Aventis holds patents for loratadine phenylephrine combinations, which are found under the brand name Alavert-D 12 Hour. These patents extend until 2030, providing the company with market exclusivity for this medication.

Sources:

[1] DrugPatentWatch.com. (n.d.). Sanofi-Aventis. Retrieved from <https://www.drugpatentwatch.com/drugs/sanofi-aventis>

[2] Mayo Clinic. (2021). Loratadine and Phenylephrine. Retrieved from <https://www.mayoclinic.org/drugs-supplements/loratadine-and-phenylephrine-oral-route/description/drg-20066533>

[3] Harvard Health Publishing. (2020). The high cost of prescription drugs, explained. Retrieved from <https://www.health.harvard.edu/blog/the-high-cost-of-prescription-drugs-explained-2020010618582>